Evidence-based IP and Patent Landscaping

Indicative publications are listed below. Please see LML members' individual pages for full publication lists.

M Aboy, WN Price and S Raker ‘Mapping the patent landscape of medical machine learning’ (2023) 41(4) Nature Biotechnology’ 461-46.

M Aboy, LC Druedahl and T Minssen ‘Evidence-based IP research’ in Research Handbook on Empirical Studies in Intellectual Property Law (2023) Edward Elgar Publishing 120-136.

J Liddicoat, ‘New insights into the amount of R & D for new uses of generic drugs’ (2023) Generics and Biosimilars Initiative (Online). 

A Sagar, K Liddell, J Liddicoat, M Aboy, ‘Patent eligibility and precision medicine: emerging technologies, legal flux and empirical methods’ in N Hawkins (ed) Patenting Biotechnical Innovation (Edward Elgar Publishing, 2022). 

M Aboy, K Liddell, M Jordan, C Crespo, and J Liddicoat, ‘European patent protection for medical uses of known products and drug repurposing’ (2022) 40(4) Nature Biotechnology 465. 

M Aboy, T Minssen, and M Kop, ‘Mapping the Patent Landscape of Quantum Technologies: Patenting Trends, Innovation and Policy Implications’ (2022) 53(6) International Review of Intellectual Property and Competition Law 853. 

M Aboy, K Liddell, J Liddicoat, C Crespo and M Jordan, 'Mapping the European Patent Landscape for Medical Uses of Known Products'  (2021) Nature Biotechnology.

Z Fritz, J Huppert, K Liddell et al., 'Ethical principles and a practical approach to support policy making through the next phases of the COVID-19 pandemic and beyond' (March 2021) Clinical Medicine.

M Aboy and J Sherkow,'IP and FDA Regulation of De Novo Medical Devices' in I G Cohen (ed.) Innovation & Protection: The Future of Medical Device Regulation (2021). 

J Liddicoat, K Liddell and M Aboy, 'The Effects of Myriad and Mayo on Molecular-Test Development in the United States and Europe: Interviews from the Frontline' (2020) 22 Vanderbilt Journal of Entertainment and Technology Law 785. 

M Aboy, C Crespo, K Liddell, T Minssen and J Liddicoat,'After six years, what has been Mayo’s impact on patent applications related to biotech, diagnostics, and personalized medicine?' (2019) 37(5) Nature Biotechnology 513.  

K Liddell, J Liddicoat and M Jordan, 'IP Policies for Large Bioresources: the fiction, fantasy and future of openness' in T Minssen, J R Hermann and J Schovsbo (eds.) Global Genes, Local Concerns – Legal, Ethical and Scientific Challenges in International Biobanking (Edward Elgar Publishing, 2019).  

D Nicol, R Dreyfuss, E Gold, W Li, J Liddicoat and G Van Overwalle, 'International Divergence in Gene Patenting' (2019) 20 Annual Review of Genomics and Human Genetics 1.  

J Liddicoat, K Liddell and M Aboy, 'The Effects of Myriad and Mayo on Molecular Test Development in the US and Europe: Interview from the Frontline' (2019) Vanderbilt Journal of Entertainment and Technology Law.

J Liddicoat, K Liddell, A McCarthy, S Hogarth, M Aboy, D Nicol, S Patton and M Hopkins, 'Continental Drift? Do European Clinical Genetics Laboratories have  Patent Problem?' (2019) 27 European Journal of Human Genetics 997. 

J Liddicoat and J de Werra, 'When can Exclusive Licensees Initiate Patent Infringement Proceedings? Lessons for Global IP Licensing Transactions from Two Recent UK Cases' (2019) 14(1) Journal of Intellectual Property Law & Practice 2.

M Aboy,K Liddell, J Liddicoat,C Crespo and M Jordan, “After Myriad, what makes a gene patent claim ‘markedly different’ from Nature?” (2017) 35 Nature Biotechnology 820.

J Liddicoat, “Divided Performance of Patented Methods in Australia: a Call to Codify Procured Infringement” (2018) 41(1) University of New South Wales Law Journal 252.

M Aboy, C Crespo, K Liddell, N Davey, J Liddicoat, T Minssen, 'One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?', (2020) 38 Nature Biotechnology 279-283.

M Aboy, K Liddell, C Crespo, I G Cohen, J Liddicoat, S Gerke, 'How deos emerging patent case law in the US and Europe affect precision medicine?', (2019) 37 Nature Biotechnology 1118-1125.

M Aboy, C Crespo, K Liddell, T Minssen, J Liddicoat, 'Mayo's impact on patent applications related to biotechnology, diagnostics and personalized medicine', (2019) 37 Nature Biotechnology 513-518.

M Aboy, C Crespo, K Liddell, J Liddicoat, M Jordan, 'Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?', (2018) 36 Nature Biotechnology 1146-1149.

M Aboy, J Liddicoat, K Liddell, M Jordan, C Crespo, 'After Myriad, what makes a gene patent claim 'markedly different' from nature?', (2017) 35 Nature Biotechnology 820-225.

M Aboy, K Liddell, J Liddicoat, C Crespo, 'Myriad's impact on gene patents', (2016) 34 Nature Biotechnology 1119-1123.

For more information about the LML's Consulting and Contract Services regarding patent landscaping, see here.